Efficacy of poziotinib in HER2 exon 20 insertion NSCLC patients who received prior platinum-based and HER2 targeted therapies

被引：0
|
作者：
Prelaj, A. [1 ]
Le, X. [2 ]
Proto, C. [3 ]
Baik, C. S. [4 ]
Tchekmedyian, N. [5 ]
Heymach, J. [6 ]
Bhat, G. [7 ]
Cornelissen, R. [8 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Oncol Med Torac Dept, Milan, Italy
[2] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck, Houston, TX USA
[3] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[4] Univ Washington, Dept Med Oncol, Seattle Canc Care Alliance, Seattle, WA USA
[5] City Hope Natl Med Ctr, Med Oncol, Comprehens Canc Ctr, Duarte, CA USA
[6] MD Anderson Canc Ctr, Thorac Oncol, Houston, TX USA
[7] Spectrum Pharmaceut, Dept Clin Sci, Irvine, CA USA
[8] Erasmus MC Univ, Pulm Med, Med Ctr, Rotterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2422
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1389P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Poziotinib: Case Report of Compassionate Drug Use
    Pandey, Apurva
    Brufsky, Adam M.
    CLINICAL BREAST CANCER, 2019, 19 (01) : E7 - E11
  • [42] Prognosis and Categorization of HER2 Fluorescent In-situ Hybridization (FISH) Results in Patients with Invasive Breast Cancer Who Received HER2 Targeted Agents: Analysis of 226 Patients
    Alhamar, Mohamed
    Alkamachi, Bassam
    Mehrotra, Harshita
    Sanchez, Jessica
    Schultz, Daniel
    Chitale, Dhananjay
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 100 - 101
  • [43] Efficacy and safety of poziotinib in treatment-naive HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4
    Sun, S.
    Prelaj, A.
    Baik, C.
    Le, X.
    Garassino, M.
    Wollner, M.
    Haura, E.
    Piotrowska, Z.
    Socinski, M.
    Dreiling, L.
    Bhat, G.
    Lebel, F.
    Cornelissen, R.
    ANNALS OF ONCOLOGY, 2022, 33 : S13 - S13
  • [44] Prognosis and Categorization of HER2 Fluorescent In-situ Hybridization (FISH) Results in Patients with Invasive Breast Cancer Who Received HER2 Targeted Agents: Analysis of 226 Patients
    Alhamar, Mohamed
    Alkamachi, Bassam
    Mehrotra, Harshita
    Sanchez, Jessica
    Schultz, Daniel
    Chitale, Dhananjay
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 100 - 101
  • [45] High activity of poziotinib in G778_P780dup HER2 exon 20 insertion mutations in non-small cell lung cancer (NSCLC)
    Le, X.
    Sun, S.
    Haura, E.
    Bertino, E.
    Baik, C.
    Mamdani, H.
    Leu, S.
    Thiagalingam, A.
    Kokhreidze, J.
    Lebel, F.
    Socinski, M. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1084 - S1085
  • [46] Targeted therapies for HER2 breast cancer: A view of the landscape
    Rana V.
    Swaby R.F.
    Current Breast Cancer Reports, 2011, 3 (1) : 55 - 62
  • [47] HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France
    Debieuvre, D.
    Macouillard, P.
    Quantin, X.
    Berktas, M.
    Girard, N.
    Valette, C. Audigier
    Filleron, T.
    Musilli, S.
    Bosquet, L.
    Perol, M.
    ANNALS OF ONCOLOGY, 2023, 34
  • [48] Discovery and characterization of potent and selective HER2 exon20 insertion mutant inhibitors
    Nam, Ho Yeon
    Jang, Sun Young
    Jeon, Jiyoung
    Yoo, HyungSeok
    Byun, Jooyun
    Lee, Gunwoo
    Lee, Youngjoo
    Kim, Yu-Yon
    Jeon, Soye
    Ahn, Young Gil
    CANCER RESEARCH, 2024, 84 (06)
  • [49] HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
    Zhang, Xinyong
    Lv, Jialin
    Wu, Yuhua
    Qin, Na
    Ma, Li
    Li, Xi
    Nong, Jingying
    Zhang, Hui
    Zhang, Quan
    Yang, Xinjie
    Shi, Huibo
    Wang, Jinghui
    Zhang, Shucai
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [50] First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma
    Luan, Tao
    Lin, Xinqing
    Xie, Xiaohong
    Yang, Gang
    Wang, Shuaiying
    Hao, Jianqing
    Zhou, Chengzhi
    ANTI-CANCER DRUGS, 2024, 35 (08) : 757 - 760
12345